Host: Crystal Proud, MD

Guest: Erika Finanger, MD, MS

By completing this activity, learners will gain the skills and confidence to determine therapeutic candidacy and conduct appropriate assessments for patients with Duchenne Muscular Dystrophy (DMD) across the age spectrum, including older and non-ambulatory individuals. They will improve their ability to interpret and apply the latest clinical data to real-world scenarios and make informed decisions about treatment and monitoring. Through case-based education, learners will enhance their competence in aligning patients to appropriate therapies and managing long-term care in a rapidly evolving treatment landscape.

Guest: Raman Sankar, MD, PhD

Guest: Scott Aaronson, MD

This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

Guest: Raman Sankar, MD, PhD

Guest: Scott Aaronson, MD

This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

Guest: Raman Sankar, MD, PhD

Guest: Scott Aaronson, MD

This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

Guest: Raman Sankar, MD, PhD

Guest: Scott Aaronson, MD

This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

Guest: Raman Sankar, MD, PhD

Guest: Scott Aaronson, MD

This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

Host: Alejandro A. Rabinstein, MD, FAHA

Guest: Richard E. Pratley, MD

Guest: Jay H. Shubrook, DO, FACOFP, FAAFP

Listen to expert faculty discuss the role of GLP-1RAs in reducing stroke risk for patients with type 2 diabetes in this on-demand webcast with accompanying slides

Host: Crystal Proud, MD

Guest: John Brandsema, MD

Guest: Omer Abdul Hamid, MD

Explore the latest treatment options, age-specific management strategies, and clinical trial data for patients with Duchenne muscular dystrophy (DMD). Through expert-led discussions and real-world patient cases, you’ll gain practical insights to help you confidently navigate today’s ever-evolving treatment landscape and deliver personalized, informed care.

Host: Vera Bril, MD

Guest: Neelam Goyal, MD

Traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial for many patients in the short term but often come with unacceptable side effects. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) has created a groundbreaking paradigm shift in our approach to both the short- and longer-term management of affected patients. Join Drs. Vera Bril and Neelam Goyal as they take a deep dive into this topic and discuss how FcRn inhibitors are changing the therapeutic landscape of gMG.

Guest: Vera Bril, MD

Guest: Nicholas J. Silvestri, MD

While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.